Bluebird bio stock slides for second day on buyout news
https://seekingalpha.com/news/4412461-bluebird-bio-stock-slides-for-second-day-on-buyout-news?source=feed_sector_healthcare
Feb 24, 2025 -
0
Intelligent Bio Solutions shares fall on proposed offering of common stock
https://seekingalpha.com/news/4410611-intelligent-bio-solutions-shares-fall-on-proposed-offering-of-common-stock?source=feed_sector_healthcare
Feb 19, 2025 -
0
GRI Bio announces 1-for-17 reverse stock split to regain Nasdaq compliance
https://seekingalpha.com/news/4410603-gri-bio-announces-1-for-17-reverse-stock-split-to-regain-nasdaq-compliance?source=feed_sector_healthcare
Feb 19, 2025 -
0
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
https://seekingalpha.com/article/4758320-bio-rad-laboratories-inc-bio-q4-2024-earnings-call-transcript?source=feed_sector_transcripts
Feb 13, 2025 -
0
Kala Bio CEO Mark Iwicki Resigns, Appoints Todd Bazemore As Interim CEO; Stock Falls In Pre-Market
https://www.rttnews.com/story.aspx?Id=3511944
Feb 12, 2025 - Kala Bio, Inc. (KALA), Wednesday announced the resignation of Chief Executive Officer Mark Iwicki, effective immediately. He will continue to serve as Chair of the Board of Directors of the company.
0
Mustang Bio regains compliance with Nasdaq minimum bid price requirement
https://seekingalpha.com/news/4406486-mustang-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement?source=feed_sector_healthcare
Feb 11, 2025 -
0
Annovis Bio Prices Offering Of 5.25 Mln Shares At $4/Share, Stock Falls In Pre-Market
https://www.rttnews.com/story.aspx?Id=3508447
Feb 03, 2025 - Late-stage clinical drug platform company Annovis Bio, Inc. (ANVS), Monday announced the pricing of 5.25 million common stock and warrants to purchase an equal number of shares at a combined price of $4 per share, amounting to a total of $21 million.
0
Kronos Bio announces interim CEO; over 80% of staff reduction
https://seekingalpha.com/news/4338974-kronos-bio-stock-ceo-change-layoffs?source=feed_sector_healthcare
Nov 27, 2024 - Kronos Bio (KRON) stock gains as company appoints interim CEO Deborah Knobelman amid plans to cut 83% of workforce. Read more here.
0
Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
https://seekingalpha.com/article/4740127-why-bio-rad-laboratories-is-overvalued-a-fundamental-and-dcf-analysis?source=feed_tag_editors_picks
Nov 25, 2024 - Bio-Rad’s innovation is slowing, with declining patents and negative ROE. See why BIO stock is overvalued by 20.10% and facing challenges in 2024.
0
Cabaletta Bio Reveals CABA-201's Positive Clinical Safety And Efficacy Data
https://www.rttnews.com/story.aspx?Id=3491197
Nov 18, 2024 - Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on autoimmune diseases, announced Monday new and updated clinical data on CABA-201, presenting positive clinical safety and efficacy results.
0